Business Wire

GALDERMA

Share
Galderma Launches ‘NEXT’, a Ground-Breaking Trend Report That Unveils the Future of Aesthetics

Galderma, the emerging pure-play dermatology category leader, is proud to present “NEXT by Galderma.” A ground-breaking report, NEXT takes a deep-dive into the global aesthetics trends set to shape 2024 and beyond. This project is the culmination of a year of comprehensive trend-forecasting research, conducted in collaboration with a network of renowned experts.

Aesthetics is increasingly becoming part of holistic beauty and well-being routines, which are, in turn, driving the category’s projected growth. By 2028, the aesthetics market is predicted to nearly double in value, reaching $25.9 billion.1

NEXT by Galderma offers a future-forward perspective on the aesthetics industry. The report identifies six key emerging trends, bolstered by three core macro movements that are supporting industry growth. These six key trends have the potential to shape the aesthetics landscape and become mainstream in the future. The report takes an in-depth look at these trends from a neutral standpoint, as well as at the societal and cultural aspects underpinning the evolution of the aesthetics industry.

Commissioned by Galderma and based on research from a leading trend-forecasting authority, the report is informed by extensive data and analysis. NEXT by Galderma was co-developed by a network of almost 40 of the world’s leading healthcare professionals and esteemed beauty and skincare influencers.

 

“In partnership with a renowned trend-forecasting agency, and in collaboration with revered healthcare professionals and influencers, we’ve identified six trends poised to shape the future of aesthetics. The trends that we see emerging now have the potential to become bigger and impact consumer decisions regarding their beauty and skincare choices. At Galderma, everything we do in the world of aesthetics is a manifestation of our belief in “Aesthetic Possibilities, Shaped Together.” It’s a new, more collaborative and future-facing approach that is at the core of NEXT by Galderma.”

 

GERRY MUHLE

HEAD OF GLOBAL PRODUCT STRATEGY

GALDERMA

 

NEXT by Galderma: The six trends that are anticipated to shape consumer demand in aesthetics

  1. Proactive Beauty: Addressing aging before it is apparent has become paramount. The rise of “prejuvenation” treatments, which focus on prevention rather than cure, reflects today’s zeitgeist. For aesthetics, this means an increased shift toward early intervention.
  2. Mindful Aesthetics: The ethos of mindful beauty has reached the aesthetics market. Consumers are increasingly embracing products with minimal environmental impact that align with their ethical values and provide natural-looking results. Additionally, there is demand for products that seamlessly integrate with the body, indicating a push-back against artifice.
  3. Fast Aesthetics: That trends in fashion and cosmetics come and go is nothing new. But the addition of aesthetics treatments into the mix is a more recent—and noteworthy—development. More and more people now want to use aesthetics to mimic the latest fast-moving trends.
  4. Beauty Fandom: There is a new and more extreme take on fandom at play in the aesthetics world today. This trend indulges in fascination with niche idolization—from cultural icons to digital filters, anime, and beyond—which is leading to a desire for metamorphosis.
  5. Expressionality: There is greater interplay between a sense of self and self-expression. We live in an era that encourages individuality in fashion, styling, hair, makeup and, now, aesthetic treatments. This trend celebrates the empowerment that comes from creating and enhancing one’s identity with aesthetics.
  6. Cancelling Age: Beauty today is for every age, at any age. We are cancelling expectations of what certain ages “should look like,” as consumers employ aesthetics to express their ageless attitude. This trend shows how the evolving desire to not be defined by our age is increasing demand to preserve and enhance beauty, rather than solely reverse aging.

The six trends are underpinned by three macro movements:

  1. Increasing accessibility: More convenient, more affordable, more inclusive. The exponential rise of minimally invasive treatments, as well as increased access to treatments via new clinic locations and treatment options, are factors that have reshaped the beauty industry. The desire for inclusivity has had a major impact on the world of aesthetics at large.
  2. Advancements in science and technology: The rise of aesthetic tech, new product innovations and improvements on existing products have expanded not only the variety of treatment options available, but also their appeal.
  3. Social community: Social media has heightened consumer awareness and understanding around aesthetic treatments. Aesthetic practitioners are using social media to garner sizeable followings, highlighting that the world of aesthetics has a far-reaching platform of increasing influence.

As Galderma continues to navigate what lies ahead, driven by “Aesthetic Possibilities, Shaped Together,” there remains a firm focus on advancing dermatology for every skin story. The skin we’re in shapes our lives. That’s why Galderma’s unparalleled portfolio—along with our commitment to staying at the forefront of emerging technologies, medical education, thought leadership and training—is essential to shaping the future of aesthetics.

To view the abridged version of the NEXT by Galderma report, click here.

About Galderma

Galderma is the emerging pure-play dermatology category leader, present in approximately 90 countries. We deliver an innovative, science-based portfolio of premium flagship brands and services that span the full spectrum of the fast-growing dermatology market through Injectable Aesthetics, Dermatological Skincare and Therapeutic Dermatology. Since our foundation in 1981, we have dedicated our focus and passion to the human body’s largest organ—the skin—meeting individual consumer and patient needs with superior outcomes in partnership with healthcare professionals. Because we understand that the skin we’re in shapes our lives, we are advancing dermatology for every skin story. For more information: www.galderma.com.

References:

  1. Markets and Markets (2022): Medical Aesthetics Market - Global Forecast to 2027. Hadapsar: Markets and Markets, pp. 1–257. Available at: https://www.marketsandmarkets.com/Market-Reports/medical-aesthetics-market-885.html

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240206624555/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Transition Industries Signs Strategic Agreements for the Pacifico Mexinol Project, the Largest Standalone Ultra-Low Carbon Chemical Production Facility in the World30.6.2025 20:30:00 CEST | Press release

Pacifico Mexinol project, a 6,130 MT per day ultra-low carbon methanol production facility worth more than US$3.3b will be located near Topolobampo, Ahome, Sinaloa. Once operational in 2029, Pacifico Mexinol is poised to be the largest standalone ultra-low carbon chemical production facility in the world. Transition Industries LLC, a developer of world-scale, net-zero carbon emissions methanol and green hydrogen projects in North America, held a signing event for an Engineering, Procurement, and Construction (EPC) contract with the consortium of Samsung E&A Co., Ltd. (Samsung E&A), Grupo Samsung E&A Mexico, S.A. de C.V., and Techint Engineering and Construction for the Pacifico Mexinol project located in Ahome, Sinaloa, Mexico, which is contingent upon the fulfillment of customary conditions precedent and obtainment of all required approvals. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250630940954/en/ MAIRE group’s techn

Westinghouse and ITER Sign a $180M Contract to Advance Nuclear Fusion30.6.2025 15:45:00 CEST | Press release

The contract includes the assembly of the fusion reactor’s vacuum vessel, a key milestone which gets the project closer to replicating fusion energy on Earth Westinghouse Electric Company and ITER signed a contract for $180 million for the assembly of the vacuum vessel for the fusion reactor. This is a key milestone in the construction of the ITER reactor, leading the way toward the use of fusion as a practical future source of reliable carbon-free energy. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250630497810/en/ The ITER Tokamak pit with the two vacuum vessel sector modules installed. Westinghouse has participated in the fabrication of the sectors of the vacuum vessel, as part of the Fusion for Energy (F4E) Consortium with its partners Ansaldo Nucleare and Walter Tosto. Westinghouse will be responsible for completing the vacuum vessel which is ITER’s most critical component: a hermetically sealed, double-walled steel

Monetate Acquires SiteSpect to Deliver AI-Native Personalization and Testing at Enterprise Scale30.6.2025 15:00:00 CEST | Press release

Monetate’s Real-Time Personalization Unites with SiteSpect’s Zero-Flicker Testing to Optimize Digital Experiences with Unmatched Speed, Precision, and SecurityNow Global Ecommerce and Digital Experience Leaders Can Access a Best-in-Class, Enterprise-Grade Personalization, Testing, and Optimization Platform Monetate, the leading AI-driven personalization platform, today announced it has acquired SiteSpect, a leader in A/B testing, to drive next-generation digital experience optimization. This acquisition accelerates Monetate’s vision to deliver intelligent, intentional, and individualized experiences at scale, powered by agentic AI and backed by the industry’s most advanced, enterprise-grade infrastructure. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250630514541/en/ The combination of Monetate’s real-time personalization and SiteSpect’s zero-flicker testing will yield an industry-first solution for enterprise-grade person

SS&C Blue Prism Recognized as a Gartner® Magic Quadrant™ RPA Leader for the Seventh Consecutive Year30.6.2025 15:00:00 CEST | Press release

SS&C Technologies Holdings, Inc. (Nasdaq: SSNC) today announced that SS&C Blue Prism has been recognized as a Leader in the 2025 Gartner Magic Quadrant for Robotic Process Automation (RPA). “We’re delighted SS&C Blue Prism has been named a Leader in the Gartner Magic Quadrant for Robotic Process Automation for the seventh year running,” said Bill Stone, CEO and Chairman of SS&C Technologies. “SS&C Blue Prism combines market-leading RPA and orchestration technologies with the latest artificial intelligence so organizations can tackle more complex tasks and dynamic business processes. We’ve scaled to more than 2,700 digital workers and AI agents across our own operations, resulting in over $200 million in annual savings. With SS&C leading the charge on deployment, customers can be confident in rolling out SS&C’s automation solutions securely, effectively, and responsibly.” More than 2,800 companies worldwide leverage SS&C Blue Prism for AI-powered automation, helping organizations delive

Takeda Announces U.S. FDA Approval of GAMMAGARD LIQUID ERC, the Only Ready-to-Use Liquid Immunoglobulin Therapy with Low Immunoglobulin A (IgA) Content130.6.2025 14:00:00 CEST | Press release

GAMMAGARD LIQUID ERC [immune globulin infusion (human)] with Less Than or Equal to 2 µg/mL IgA in a 10% Solution is Approved for Intravenous or Subcutaneous Use in People Aged Two and Older with Primary Immunodeficiency1U.S. Commercialization of GAMMAGARD LIQUID ERC Projected to Begin in 2026Company Announces Future Manufacturing Discontinuation End Date for Takeda's First-Generation Low-IgA Product, A Freeze-Dried Formulation in Company’s Differentiated Immunoglobulin Portfolio of Ready-to-Use Liquids2 Takeda(TSE:4502/NYSE:TAK) today announced that the U.S. Food and Drug Administration (FDA) has approved GAMMAGARD LIQUID ERC [immune globulin infusion (human)] with less than or equal to 2 µg/mL IgA in a 10% solution, the only ready-to-use liquid immunoglobulin (IG) therapy with low immunoglobulin A (IgA) content, as replacement therapy for people two years of age and older with primary immunodeficiency (PI). As a ready-to-use liquid, GAMMAGARD LIQUID ERC may help ease the administratio

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye